Abstract
Introduction
Despite its initial description over 25 years ago, there is little known about the course of eosinophilic esophagitis (EoE) after an initial course of medical or dietary treatment. We aim to assess the long-term symptomology and quality of life (QoL) metrics in patients 10 years after initial treatment for eosinophilic esophagitis.
Methods
Inclusion criteria: single center study of EoE patients diagnosed over 10 years ago with completion of an 18-question structured telephone interview. A cohort of patient’s prospectively underwent an esophageal barium exam, esophageal sponge cytology, and evaluation by a esophagologist at greater than 10 years’ time since original diagnosis.
Results
A total of 54 patients were included in the study. The average age at follow-up was 55.0, with the majority male (64.8%). At the original diagnosis, 62.9% and 37.0% were initially treated with topical steroids and a proton pump inhibitor (PPI), respectively,compared to 59.3% and 7.4% after 10 years, and 7.4% of patients reported a history of dilatations. Only 11.8% noted avoidance of trigger foods, with 62.7% noting an unlimited diet without caution. QoL decrease secondary to EoE was noted to be trivial to minimal in 56.9% of patients, mild in 19.6%, moderate in 15.7% and severe in 7.8%. In the prospective follow-up cohort, the results of telephone survey results matched the direct physician-obtained interview in 88% of cases.
Conclusion
Ten years after diagnosis, treated EoE is rarely continually symptomatic, requires mainly PPI-based therapies and is associated with a minimal decrease in QoL scores.
Similar content being viewed by others
Abbreviations
- EoE:
-
Eosinophilic esophagitis
- GERD:
-
Gastroesophageal reflux disease
- hpf:
-
High powered field
- PPI:
-
Proton pump inhibitor
- PPI-REE:
-
Proton pump inhibitor responsive esophageal eosinophilia
References
Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679.
Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3.
Prasad GA, Talley NJ, Romero Y, et al. Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol. 2007;102:2627–2632.
Mackenzie SH, Go M, Chadwick B, et al. Clinical trial: eosinophilic esophagitis in patients presenting with dysphagia: a prospective analysis. Aliment Pharmacol Ter. 2008;28:1140–1146.
Straumann A. The natural history and complications of eosinophilic esophagitis. Thorac Surg Clin. 2011;21:575–587.
Podboy A, Katzka DA, Enders F, et al. Oesophageal narrowing on barium oesophagram is more common in adult patients with eosinophilic oesophagitis than PPI-responsive oesophageal eosinophilia. Aliment Pharmacol Therap. 2016;. https://doi.org/10.1111/apt.13601.
Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145:1230e2–1236e2.
Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows tha eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79:577e4–585e4.
Straumann A, Spichtin H-P, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125:1660–1669.
Warners M, Nijhuis RAO, De Wijkerslooth LR, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol. 2018;113:836–844.
Ronkainen J, Talley NJ, Aro P, et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut. 2007;56:615–620. https://doi.org/10.1136/gut.2006.107714.
Mansoor E, Cooper GS. The 2010–2015 prevalence of eosinophilic esophagitis in the United States: a population-based study. Dig Dis Sci. 2016;61:2928–2934. https://doi.org/10.1007/s10620-016-4204-4.
Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin N Am. 2014;43:201–218. https://doi.org/10.1016/j.gtc.2014.02.002.
Menard-Katcher P, Marks KL, Liacouras CA, et al. The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood. Aliment Pharmacol Ther. 2013;37:114–121.
Dellon ES, Erichsen R, Baron JA, et al. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther. 2015;41:662–670.
Hruz P, Straumann A, Bussmann C, et al. Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol. 2011;128:1349–1350.
Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol. 2005;115:418–419.
Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2009;7:1055–1061.
Whitney-Miller CL, Katzka D, Furth EE. Eosinophilic esophagitis: a retrospective review of esophageal biopsy specimens from 1992 to 2004 at an adult academic medical center. Am J Clin Pathol. 2009;131:788–792.
Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–246. https://doi.org/10.1001/jamainternmed.2015.7193.
Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementiaa pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416. https://doi.org/10.1001/jamaneurol.2015.4791.
Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118:e36–e42. https://doi.org/10.1161/CIRCRESAHA.116.308807.
Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363.
Grudell ABM, Alexander JA, Enders FB, et al. Validation of the Mayo Dysphagia Questionnaire. Dis Esophagus. 2007;20:202–205. http://hdl.handle.net/2027.42/71625.
Bohm M, Jacobs JW, Gupta A, Gupta S, Wo JM. Most children with eosinophilic esophagitis have a favorable outcome as young adults. Dis Esophagus. 2017;30:1–6. https://doi.org/10.1111/dote.12454.
Van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1815–2300.
Molina-Infante J, Rivas MD, Hernandez‐Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–965.
Moawad FJ, Wells JM, Johnson RL, et al. Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2015;42:231–238.
Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–2317.https://doi.org/10.1007/s10620-009-0951-9.
Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150:581–5900000.
Krishna SG, Kakati BR, Olden KW, et al. Treatment of eosinophilic esophagitis: Is oral viscous budesonide superior to swallowed fluticasone spray? Gastroenterol Hepatol. 2011;7:55–59.
Albert D, Heifert TA, Min SB, et al. Comparisons of fluticasone to budesonide in the treatment of eosinophilic esophagitis. Dig Dis Sci. (Epub ahead of print). https://doi.org/10.1007/s10620-016-4110-9.
Lipka S, Kumar A, Miladinovic B, et al. Systematic review with network meta-analysis: comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43:663–673.
Acknowledgments
Study supported by an unrestricted grant from Mayo Clinic Rochester Gastroenterology.
Author information
Authors and Affiliations
Contributions
Dr. Podboy is a Gastroenterology and Hepatology fellow at Stanford University Hospital in Stanford, California. He was instrumental in the design and conduct of the study, data collection, and writing of the manuscript. Crystal Lavey is a research assistant in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. She assisted in the collection of the data. Debra Geno is a research assistant in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. She assisted in the collection of the data. Kristin Mara is a statistician in the Department of Health Sciences Research and assisted in the statistical methods, analysis and critical appraisal of the manuscript. Dr. Kanna is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in the critical appraisal of the manuscript. Dr. Katzka is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in data interpretation, writing and critical appraisal of the manuscript. Dr. Ravi is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in the critical appraisal of the manuscript. Dr. Alexander is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in the design and conduct of the study, data collection, critical appraisal and writing of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Statement on the welfare of animals
This article does not contain any studies with animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Podboy, A.J., Lavey, C., Mara, K. et al. Eosinophilic Esophagitis Is Rarely Continually Symptomatic 10 Years After an Initial Treatment Course in Adults. Dig Dis Sci 64, 3568–3578 (2019). https://doi.org/10.1007/s10620-019-05636-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-019-05636-0